In:
Oncology, S. Karger AG, Vol. 80, No. 1-2 ( 2011), p. 97-101
Abstract:
〈 i 〉 Objective: 〈 /i 〉 The aim of this study was to investigate the effect of gemcitabine and oxaliplatin combination chemotherapy on refractory pancreatic cancer. 〈 i 〉 Methods: 〈 /i 〉 Patients with advanced pancreatic cancer refractory to gemcitabine and S-1 were treated with gemcitabine 1,000 mg/m 〈 sup 〉 2 〈 /sup 〉 over 30 min and oxaliplatin 85 mg/m 〈 sup 〉 2 〈 /sup 〉 over 120 min on days 1 and 15. Treatment was repeated every 4 weeks and tumor response was assessed every two cycles by RECIST version 1.0. 〈 i 〉 Results: 〈 /i 〉 Twenty-two patients with pathologically confirmed pancreatic cancer were enrolled. The treatment was administered as a second-line chemotherapy in eighteen patients (82%) and as a third-line chemotherapy in four patients (18%). Tumor response did not occur in any of the cases. Thirteen patients demonstrated stable diseases, and the disease control rate was 59%. Median overall survival and time to progression were 6.8 months (95% CI, 2.8–11.5) and 2.6 months (95% CI, 1.5–3.8), respectively. Median overall survival from the first-line chemotherapy was 22.7 months (95% CI, 14.8–24.4). The major grade 3/4 adverse events included neutropenia (14%), anorexia (23%), and peripheral neuropathy (14%). 〈 i 〉 Conclusions: 〈 /i 〉 Gemcitabine and oxaliplatin combination chemotherapy was tolerable but had limited activity in patients with advanced pancreatic cancer in a refractory setting.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2011
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink